Clinical Trial Update: Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetics data for a recombinant Factor XIII product in patients with congenital Factor XIII deficiency are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Xiii Deficiency

Drugs mentioned

• Recombinant Factor XIII (Factor XIII, recombinant)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 1 | Status: COMPLETED